5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Items 701–800 of 1,028
Carvalho, R. D. D. O., Breyner, N. M., Garcia, Z. M., Rodrigues, N. M., Lemos, L., Maioli, T. U., de Souza, D. D. G., Cara, D. C., Faria, A. M. C., Langella, P., et al. (2017) · Microbial Cell Factories · doi:10.1186/s12934-017-0624-x · Cited by 67
“cancer and normal cells, such as the enterocytes lining the digestive tract [5, 6].”
BackgroundNot Just Antibiotics: Is Cancer Chemotherapy Driving Antimicrobial Resistance?
Papanicolas, L. E., Gordon, D., Wesselingh, S. L., & Rogers, G. B. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.10.009 · Cited by 70
Liu, S., Lin, H., Wang, D., Li, Q., Luo, H., Li, G., Chen, X., Li, Y., Chen, P., Zhai, B., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0087-0 · Cited by 65
Chen, D., Zhao, J. L., & Cong, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01442 · Cited by 76
“50%-80% of patients developed intestinal mucositis when undergoing 5-Fu-based chemotherapy (Longley et al., 2003; Smith et al., 2008).”
BackgroundKim, S., Choung, S., Sun, R., Ung, N. M., Hashemi, N., Fong, E. J., Lau, R., Spiller, E. R., Gasho, J. O., Foo, J., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220915827 · Cited by 73
Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer
Khomiak, A., Brunner, M., Kordes, M., Lindblad, S., Miksch, R. C., Öhlund, D., & Regel, I. (2020) · Cancers · doi:10.3390/cancers12113234 · Cited by 73
“This enzyme is involved in the catalyzation of the chemotherapeutic drug 5-fluorouracil (5-FU) used in several treatment regimens for pancreatic cancer [57,58].”
BackgroundAnstee, J. E., Feehan, K. T., Opzoomer, J. W., Dean, I., Muller, H. P., Bahri, M., Cheung, T. S., Liakath‐Ali, K., Liu, Z., Choy, D., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2023.06.006 · Cited by 70
“Treatment of tumor-bearing MMTV-PyMT mice with 5-fluorouracil (5-FU), a chemotherapeutic that has been used in the clinic 48 and that has been demonstrated to have immune-stimulatory capabilities, 49,50 did not significantly affect tumor growth in WT mice (Figures 4F and 4G).”
Akbar, M. U., Khattak, S., Khan, M. I., Saddozai, U. A. K., Ali, N., Alasmari, A. F., Zaheer, M., & Badar, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1265440 · Cited by 71
“However, it has a rapid degradation rate (5 – 10 min) which hampers its broad clinical ef fi cacy (Longley et al., 2003).”
Milczarek, M., Psurski, M., Kutner, A., & Wietrzyk, J. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-294 · Cited by 66
“5-Fluorouracil (5-FU) is one of the oldest anticancer drugs and is still used in the treatment of colorectal cancer [21,22].”
BackgroundWang, B., Feng, P., Xiao, Z., & Ren, E.-C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.025 · Cited by 66
“Treatment of cells with chemotherapeutic drug 5fluorouracil has been shown to induce rapid accumulation of p53 [22].”
BackgroundOguri, T., Achiwa, H., Bessho, Y., Muramatsu, H., 前田, 浩., Niimi, T., Sato, S., & Ueda, R. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.05.003 · Cited by 64
“In contrast, other first metabolic enzymes, namely orotate phosphoribosyltransferase (OPRT) and thymidine phosphorylase (TP), catalyze synthesis of active metabolites, resulting in disruption of the action of TS and DNA or RNA synthesis [1].”
BackgroundInfluentialA role for orexin in cytotoxic chemotherapy-induced fatigue
Weymann, K. B., Wood, L. J., Zhu, X., & Marks, D. L. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2013.11.003 · Cited by 68
Gene signatures of drug resistance predict patient survival in colorectal cancer
Zheng, Y., Zhou, J., & Tong, Y. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.45 · Cited by 64
Qiao, J., Gu, C., Shang, W., Du, J., Yin, W. H., Zhu, M., Wang, W., Han, M., & Lu, W. (2011) · Food and Chemical Toxicology · doi:10.1016/j.fct.2011.03.033 · Cited by 71
“5-FU is also frequently used for colorectal cancer (Longley et al., 2003).”
BackgroundDeisenroth, C., & Zhang, Y. (2011) · Genes & Cancer · doi:10.1177/1947601911409737 · Cited by 76
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
Vuaroqueaux, V., Urban, P., Labuhn, M., Delorenzi, M., Wirapati, P., Benz, C. C., Flury, R., Dieterich, H., Spyratos, F., Eppenberger, U., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1681 · Cited by 64
“Since E2F1 is co-expressed or regulates genes such as TYMS, TK1 and TOP2A, which were mechanistically linked with response to 5-fluorouracil and anthracycline-based therapy [16,29-32], however, our results with respect to specific chemotherapy response should be further investigated.”
ResultOne-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling
Corbin, J. M., & Ruiz-Echevarría, M. J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081208 · Cited by 71
“Furthermore, the TS inhibitor, 5-fluorouracil (5-FU), is used in the treatment of multiple cancers, especially colon cancer [47].”
BackgroundBehrooz, A. B., Nabavizadeh, F., Adiban, J., Ardestani, M. S., Vahabpour, R., Aghasadeghi, M. R., & Sohanaki, H. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12670 · Cited by 64
Deciphering metabolic rewiring in breast cancer subtypes
Ogrodzinski, M. P., Bernard, J. J., & Lunt, S. Y. (2017) · Translational research · doi:10.1016/j.trsl.2017.07.004 · Cited by 73
Sakatani, A., Sonohara, F., & Goel, A. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy186 · Cited by 71
“The anticancer effects of 5-FU are exerted through inhibition of thymidylate synthase (TYMS), as well as by incorporation of its metabolites into RNA and DNA (5).”
BackgroundInfluentialWang, C.-C., Chen, X., Qu, J., Sun, Y., & Li, J. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00129 · Cited by 66
Hou, G., Yuan, X., Li, Y., Hou, G., & Liu, X. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00781-9 · Cited by 70
Liao, Z., Sordet, O., Zhang, H., Kohlhagen, G., Antony, S., Gmeiner, W. H., & Pommier, Y. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1302 · Cited by 64
Meli, L., Barbosa, H. S. C., Hickey, A. M., Gasimli, L., Nierode, G., Diogo, M. M., Linhardt, R. J., Cabral, J. M. S., & Dordick, J. S. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.04.004 · Cited by 63
“…contrast, the response to the antiproliferative and neurotoxic compounds tested seems to be consistent overall with published data on hNSC lines, thus demonstrating adequate sensitivity to detect adverse effects of target compounds (Breier et al., 2008; Buzanska et al., 2009; Longley et al., 2003).”
InfluentialLong Non-Coding RNA: Dual Effects on Breast Cancer Metastasis and Clinical Applications
Huang, Q.-Y., Liu, G., Qian, X., Tang, L.-B., Huang, Q.-Y., & Xiong, L. (2019) · Cancers · doi:10.3390/cancers11111802 · Cited by 66
“5-FU and DOX are two e ff ective and crucial chemotherapeutics against BC [158], which can interact with DNA by hindering macro-molecular biosynthesis [159].”
Lu, C.-S., Lin, C., Chang, Y.-H., Chen, H., Chung, W.-C., Lai, W., Ho, C., Wang, T., Chen, C., Yeh, C.-L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001392 · Cited by 69
“In conclusion, our results indicate that pemetrexed can induce PD-L1 upregulation in human NSCLC cells by regulating the TS−ROS−NF-κ B regulatory axis and prime a favorable tumor microenvironment for ICB therapy (figure 6E).”
Zhang, H., Guo, M., Zhu, T., Xiong, H., & Zhu, L. (2022) · Composites Part B Engineering · doi:10.1016/j.compositesb.2022.109790 · Cited by 68
5-fluorouracil drug alters the microrna expression profiles in MCF-7 breast cancer cells
Shah, M., Pan, X., Fix, L. N., Farwell, M. A., & Zhang, B. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22517 · Cited by 67
“…has been recently shown to modify the expression levels of several protein-coding genes (Lowe et al., 1994; Petak et al., 2000;Hwang et al., 2001; Longley et al., 2003; Maxwell et al., 2003; Inokuchi et al., 2004; Hernandez-Vargas et al., 2006; Mauritz et al., 2007; Rossi et al., 2007), but the…”
BackgroundDynamics of Uracil and 5-Fluorouracil in DNA
Parker, J. B., & Stivers, J. T. (2010) · Biochemistry · doi:10.1021/bi101536k · Cited by 63
“because repair polymerases continue to reincorporate dUTP and 5-F-dUTP in a futile repair cycle (1,2,11).”
BackgroundValentino, T., Palmieri, D., Vitiello, M., Pierantoni, G. M., Fusco, A., & Fedele, M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.500 · Cited by 67
Kong, L., Wang, X., Zhang, K., Yuan, W., Yang, Q., Fan, J., Wang, P., & Liu, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137888 · Cited by 64
“5-Fu is an anti-cancer drug mainly targeting S-phase cells, and the metabolites of 5-Fu can only be incorporated into the DNA and RNA of cell cycling cells [3,4].”
BackgroundYuan, L., Liu, M., Liu, G., Li, D., Wang, Z., Wang, B., Han, J., & Zhang, M. (2016) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2016.10.023 · Cited by 63
Zuo, H., Chen, W., Cooper, H. M., & Xu, Z. P. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06421 · Cited by 65
Ohbayashi, I., Lin, C.-Y., Shinohara, N., Matsumura, Y., Machida, Y., Horiguchi, G., Tsukaya, H., & Sugiyama, M. (2017) · The Plant Cell · doi:10.1105/tpc.17.00255 · Cited by 65
“These drugs have different action mechanisms and can affect many biochemical processes such as RNA transcription and DNA replication, among which their common and sensitive target is rRNA biosynthesis (Hsiang et al., 1985; Sobell, 1985; Longley et al., 2003).”
BackgroundHaggag, Y. A., Osman, M. A., El‐Gizawy, S. A., Goda, A. E., Shamloula, M. M., Faheem, A., & McCarron, P. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.124 · Cited by 70
Țigu, A. B., Toma, V.-A., Moț, A. C., Jurj, A., Moldovan, C. S., Fischer-Fodor, E., Berindan-Neagoe, I., & Pârvu, M. (2020) · Molecules · doi:10.3390/molecules25081947 · Cited by 63
“5-FU exerts its anti-cancer effect by preventing the synthesis of DNA and RNA in the cell by significantly decreasing thymidine [10].”
BackgroundPark, J., & Kim, Y. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00781-w · Cited by 63
Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials
Mosolits, S., Nilsson, B., & Mellstedt, H. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.3.329 · Cited by 68
Esophageal cancer: The latest on chemoprevention and state of the art therapies
Bras, G. F. L., Farooq, M. H., Falk, G. W., & Andl, C. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.021 · Cited by 65
“Administration of 5-FU reduces dTMP, thereby inducing cell death (86).”
BackgroundTopical 5‐fluorouracil in dermatologic disease
Prince, G., Cameron, M. C., Fathi, R., & Alkousakis, T. (2018) · International Journal of Dermatology · doi:10.1111/ijd.14106 · Cited by 73
Modeling Cancer Using Zebrafish Xenografts: Drawbacks for Mimicking the Human Microenvironment
Cabezas‐Sainz, P., Pensado‐López, A., Sáinz, B., & Sanchez, L. E. (2020) · Cells · doi:10.3390/cells9091978 · Cited by 68
“However, if cell proliferation is reduced at lower temperatures (34 ◦C or lower) and the chemotherapeutic agent tested targets highly proliferative cells via DNA base intercalation, like 5-Fluorouracil [89], then compounds like 5-Fluorouracil may show reduced efficacy.”
BackgroundEffectiveness of different treatments for odontogenic keratocyst: a network meta-analysis
Al‐Moraissi, E. A., Kaur, A., Gomez, R. S., & Ellis, E. (2022) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2022.09.004 · Cited by 75
Predicting 5-Fluorouracil Toxicity: DPD Genotype and 5,6-Dihydrouracil: Uracil Ratio
Sistonen, J., Büchel, B., Froehlich, T. K., Kummer, D., Fontana, S., Joerger, M., Kuilenburg, A. B. P., & Largiadèr, C. R. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.126 · Cited by 62
Role of RecA and the SOS Response in Thymineless Death in Escherichia coli
Fonville, N. C., Bates, D. B., Hastings, P. J., Hanawalt, P. C., & Rosenberg, S. M. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000865 · Cited by 62
“and TLD-independently (reviewed [2]), newer drugs are being”
BackgroundMa, Y., Yang, I., Tsai, H., Huang, C., Juo, S. H., & Wang, J. (2013) · DNA and Cell Biology · doi:10.1089/dna.2013.2161 · Cited by 69
“5-FU principally works as a TS inhibitor to block the synthesis of the thymidine, and direct incorporation of 5-FU metabolites into DNA and RNA may cause strand breaks and apoptosis (Xu et al., 2002; Longley et al., 2003).”
BackgroundSmith, R. A., Loeb, L. A., & Preston, B. D. (2005) · Virus Research · doi:10.1016/j.virusres.2004.11.011 · Cited by 71
McWhirter, D., Kitteringham, N. R., Jones, R. P., Malik, H., Park, K., & Palmer, D. H. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.011 · Cited by 64
An Aptamer Intrinsically Comprising 5‐Fluoro‐2′‐deoxyuridine for Targeted Chemotherapy
Kruspe, S., & Hahn, U. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201405778 · Cited by 63
Li, Y., Farmer, R. W., Yang, Y., & Martin, R. C. G. (2016) · BMC Cancer · doi:10.1186/s12885-016-2252-y · Cited by 62
“Inside a cell, cisplatin forms a platinum complex that binds to and cross-links DNA.”
BackgroundInfluentialHoshiba, T., & Tanaka, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.08.009 · Cited by 69
Jorge, A. F., Aviñó, A. M., Pais, A. A. C. C., Eritja, R., & Fàbrega, C. (2018) · Nanoscale · doi:10.1039/c7nr08442k · Cited by 63
Li, L., Pan, D., Chen, Q., Zhang, S.-W., Xie, D., Zheng, X., & Chen, H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490871 · Cited by 65
Gao, X., Guo, L., Li, J., Thu, H. E., & Hussain, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.024 · Cited by 64
Ichikawa, W. (2006) · Gastric Cancer · doi:10.1007/s10120-006-0373-8 · Cited by 63
“In the presence of a given concentration of FdUMP and 5,10-CH2-FH4, ternary complexes are more efficiently formed in tumors with low TS expression than in those with high TS expression, resulting in greater inhibition of DNA synthesis, followed by increased cytotoxicity [10].”
BackgroundRahbar, M., Morsali, A., Bozorgmehr, M. R., & Beyramabadi, S. A. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.112495 · Cited by 61
Oral drugs in the treatment of metastatic colorectal cancer
Alfonso, P. G., Martín, A. J. M., Morán, L. O., Alsar, J. S., Pérez-Solero, G. T., Codesido, M. B., Ferrandiz, P. A. C., & Cicala, S. G. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211009001 · Cited by 64
Tune, B. X. J., Sim, M. S., Poh, C. L., Guad, R. M., Choy, K. W., Hazarika, I., Das, A., Gopinath, S. C. B., Rajan, M., Sekar, M., et al. (2022) · Journal of Oncology · doi:10.1155/2022/3249766 · Cited by 72
“This reaction provides a source of thymidylate for DNA replication and repair [22].”
BackgroundHanna, D. H., El-Mazaly, M. H., & Mohamed, R. R. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123364 · Cited by 63
AEG-1/MTDH/LYRIC in Liver Cancer
Sarkar, D. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-401676-7.00007-3 · Cited by 61
Yasuda, M., Kato, S., Yamanaka, N., Iimori, M., Utsumi, D., Kitahara, Y., Iwata, K., Matsuno, K., Amagase, K., Yabe-Nishimura, C., et al. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00535.2011 · Cited by 60
“The antimetabolite anticancer agent 5-fluorouracil (5-FU) is widely used to treat malignant tumors due to its ability to improve tumor-free status and survival rates (27).”
BackgroundChallenges of drug resistance in the management of pancreatic cancer
Sheikh, R. M., Walsh, N., CLYNES, M. M., O'Connor, R. A., & McDermott, R. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.148 · Cited by 67
Matsuoka, K., Iimori, M., Niimi, S., Tsukihara, H., Watanabe, S., Kiyonari, S., Kiniwa, M., Ando, K., Tokunaga, E., Saeki, H., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0236 · Cited by 63
“5-FU–based chemotherapy has significantly improved and produced good therapeutic results inmany patients, but some patients either acquire resistance or do not respond to 5-FU (1).”
BackgroundDonato, C. D., Lavorgna, M., Fattorusso, R., Isernia, C., Isidori, M., Malgieri, G., Piscitelli, C., Russo, C., Russo, L., & Iacovino, R. (2016) · Molecules · doi:10.3390/molecules21121644 · Cited by 63
“This drug inhibits the thymidylate synthase enzyme resulting in a depletion of thymidine, thus interfering with the incorporation of its metabolites in RNA and DNA [7].”
BackgroundMa, W., Su, H., Cheetham, A. G., Zhang, W., Wang, Y., Kan, Q., & Cui, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.015 · Cited by 62
Marangoni, E., Laurent, C., Coussy, F., Botty, R. E., Château‐Joubert, S., Servely, J., de Plater, L., Assayag, F., Dahmani, A., Montaudon, É., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3490 · Cited by 75
“We next analyzed the expression of two enzymes whose expression may influence capecitabine response: thymidylate synthase (TYMS), the target enzyme for 5-FU, and TYMP, an enzyme involved in the metabolism of 5-FU and capecitabine (22).”
BackgroundBiological Activities of Artemisinin Derivatives Beyond Malaria
Liu, X., Cao, J., Huang, G., Zhao, Q., & Shen, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190122144217 · Cited by 66
Regulation of hematopoietic stem cell aging in vivo by a distinct genetic element
Geiger, H., Rennebeck, G., & Van Zant, G. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408654102 · Cited by 62
Chu, Q. S.-C., Schwartz, G. H., Bono, J. S. D., Smith, D. A., Koch, K. M., Versola, M., Pandite, L., Arya, N., Curtright, J., Fleming, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1765 · Cited by 61
A review on biomarkers for prediction of treatment outcome in gastric cancer.
Pietrantonio, F., de Braud, F., PRAT, V. D., Perrone, F., Pierotti, M. A., Gariboldi, M., Fanetti, G., Biondani, P., Pellegrinelli, A., Bossi, I. E., et al. (2013) · PubMed · Cited by 67
Achievements in Thermosensitive Gelling Systems for Rectal Administration
Bialik, M., Kuras, M. J., Sobczak, M., & Olędzka, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115500 · Cited by 68
“5-Fluorouracil (5-FU) is an antimetabolite drug that is widely used for the treatment of cancer, particularly for colorectal cancer [102].”
BackgroundZeng, D., Wang, Y., Chen, Y., Li, D., Li, G., Xiao, H., Hou, J., Wang, Z., Hu, L., Wang, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720620 · Cited by 65
“5-Fluorouracil (5-FU) is a cytotoxic chemotherapy medication used to treat cancer, such as colorectal cancer, oesophageal cancer and stomach cancer, with the effect of blocking thymidylate synthase (1, 2).”
BackgroundLactobacillus rhamnosus GG cell-free supernatant as a novel anti-cancer adjuvant
Salemi, R., Vivarelli, S., Ricci, D., Scillato, M., Santagati, M., Gattuso, G., Falzone, L., & Libra, M. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04036-3 · Cited by 72
Ahn, J.-Y., Lee, J., Min, H., & Lee, H. (2015) · Oncotarget · doi:10.18632/oncotarget.5327 · Cited by 65
Chen, C., Yee, L. K., Gong, H., Zhang, Y., & Xu, R. Q. (2013) · Nanoscale · doi:10.1039/c3nr00781b · Cited by 60
Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs
Chen, H., Liu, L., Jones, S. A., Banavali, N. K., Kass, J. P., Li, Z., Zhang, J., Kramer, L. D., Ghosh, A. K., & Li, H. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.12.012 · Cited by 61
“Fluorouracil derivatives are known to have activity against various strains of cancer and are used clinically (Longley et al., 2003).”
BackgroundChinnathambi, S., Velmurugan, D., Hanagata, N., Aruna, P. R., & Ganesan, S. (2014) · Journal of Luminescence · doi:10.1016/j.jlumin.2014.01.063 · Cited by 60
Natural compounds to overcome cancer chemoresistance: toxicological and clinical issues
Turrini, E., Ferruzzi, L., & Fimognari, C. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.972933 · Cited by 62
Tsujie, M., Nakamori, S., Nakahira, S., Takahashi, Y. K., Hayashi, N., Okami, J., Nagano, H., Dono, K., Umeshita, K., Sakon, M., et al. (2007) · PubMed · Cited by 60
MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer
Yu, X., Li, Z., Yu, J. Q., Chan, M. T. V., & Wu, W. K. K. (2015) · Cell Proliferation · doi:10.1111/cpr.12202 · Cited by 62
In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line
Kjellström, J., Kjellén, E., & Johnsson, A. (2005) · Acta Oncologica · doi:10.1080/02841860500247552 · Cited by 64
“between the active metabolite FdUMP and thymidylate synthase [3], which is one of the targets of the drug.”
BackgroundA latent variable model for chemogenomic profiling
Flaherty, P., Giaever, G. N., Kumm, J., Jordan, M. I., & Arkin, A. P. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti515 · Cited by 71
“A closer examination of the dyclonine experiments reveals that the NEO1 heterozygous deletion strain has a fitness defect for the drug, but is only ranked 14th in the distribution for topic 6.”
Kady, A. M. E., & Farag, M. M. (2015) · Journal of Nanomaterials · doi:10.1155/2015/839207 · Cited by 60
“Anticancer drug such as 5-fluorouracil (5-FU) has been used to treat different types of cancer [1].”
BackgroundJacobs, B., Deenen, M. J., Pluim, D., van Hasselt, J. G. C., Krähenbühl, M. D., van Geel, R. M. J. M., de Vries, N., Rosing, H., Meulendijks, D., Burylo, A. M., et al. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13007 · Cited by 68
Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature
Hohenforst‐Schmidt, W., Zarogoulidis, P., Pitsiou, G., Linsmeier, B., Tsavlis, D., Kioumis, I. P., Papadaki, E., Freitag, L., Tsiouda, T., Turner, J. F., et al. (2016) · Journal of Cancer · doi:10.7150/jca.13611 · Cited by 66
“The administration of 5-FU induces cell death via thymineless death.[45] Calcium folinate stabilises the 5-FU-TS complex and enhances 5-FU's cytotoxicity.”
BackgroundSommer, J., Mahli, A., Freese, K., Schiergens, T. S., Kuecuekoktay, F. S., Teufel, A., Thasler, W. E., Müller, M., Bosserhoff, A., & Hellerbrand, C. (2016) · Oncotarget · doi:10.18632/oncotarget.14371 · Cited by 62
“5-FU does not exhibit cytotoxic properties prior to intracellular conversion to one of its active metabolites, namely 5-fluorodeoxyuridine monophosphate (5-FdUMP), 5-fluorodeoxyuridine triphosphate (5-FdUTP) or 5-fluorouridine triphosphate (5-FUTP) [1].”
BackgroundInfluentialShiiba, M., Yamagami, H., Yamamoto, A., Minakawa, Y., Okamoto, A., Kasamatsu, A., Sakamoto, Y., Uzawa, K., Takiguchi, Y., & Tanzawa, H. (2017) · Oncology Reports · doi:10.3892/or.2017.5480 · Cited by 65
Zhu, X., Sun, Y., Chen, D., Li, J., Dong, X., Wang, J., Chen, H., Wang, Y., Zhang, F., Dai, J., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.038 · Cited by 61
“On the other hand, the crosslinked structure ensures its superior serum stability [2,3].”
Dey, D. K., Chang, S. N., Vadlamudi, Y., Park, J. G., & Kang, S. C. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111529 · Cited by 64
Karasawa, H., Miura, K., Fujibuchi, W., Ishida, K., Kaneko, N., Kinouchi, M., Okabe, M., Ando, T., Murata, Y., Sasaki, H., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01112.x · Cited by 65
Kawakami, K., Graziano, F., Watanabe, G., Ruzzo, A., Santini, D., Catalano, V., Bisonni, R., Arduini, F., Bearzi, I., Cascinu, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2428 · Cited by 60
Methylation-mediated gene silencing as biomarkers of gastric cancer: A review
Nakamura, J., Tanaka, T., Kitajima, Y., Noshiro, H., & Miyazaki, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.11991 · Cited by 64
Mohammed, A. M., Osman, S. K., Saleh, K., & Samy, A. M. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01672-6 · Cited by 62
“1), interfering with thymidylate synthase enzyme action and preventing DNA replication [3].”
BackgroundOncology Therapeutics Targeting the Metabolism of Amino Acids
Muhammad, N., Lee, H. M., & Kim, J. (2020) · Cells · doi:10.3390/cells9081904 · Cited by 62
“2C and Table 2), and is used to treat many cancers, including colorectal cancer[181].”
BackgroundHeterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma
Vilà, P. C., Ravichandra, A., Lizaso, A. A., Perugorria, M. J., & Affò, S. (2023) · Hepatology · doi:10.1097/hep.0000000000000206 · Cited by 72
Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer
Yasunaga, M., & Matsumura, Y. (2014) · Scientific Reports · doi:10.1038/srep04852 · Cited by 59
Ichikawa, W., Takahashi, T., Suto, K., Shirota, Y., Nihei, Z., Shimizu, M., Sasaki, Y., & Hirayama, R. (2006) · International Journal of Cancer · doi:10.1002/ijc.22080 · Cited by 59
“The antitumor effect of 5-FU is the inhibitor of thymidylate synthase (TS), an essential DNA synthetic enzyme, by 5-fluoro-20deoxyuridine-50-monophosphate (FdUMP), as well as incorporation of 5-FU metabolites into RNA and DNA.4 The initial metabolism of 5-FU into nucleotides is essential for its action by one or more…”
BackgroundInfluentialEpigenetic changes in colorectal cancer
Jia, Y., & Guo, M. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10245 · Cited by 66
Hakim, L., Alias, E., Makpol, S., Ngah, W. Z. W., Morad, N. A., & Yusof, Y. A. M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.11.4651 · Cited by 62
“Keywords: Gelam honey - ginger - HCT 116 cells - anti-proliferation - apoptosis - 5-FU - colon cancer (TS) and disrupting DNA & RNA synthesis (Longley et al., 2003) While its survival benefit has been firmly established, clinical applications of the drug have been greatly restricted due to the…”
BackgroundUracil–DNA Glycosylase Expression Determines Human Lung Cancer Cell Sensitivity to Pemetrexed
Weeks, L. D., Fu, P., & Gerson, S. L. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0172 · Cited by 61
“Increased intratumor levels of TYMS, observed in highly proliferating tumors, limit dTTP pool depletion and contribute to TYMS inhibitor resistance (14, 39).”
Background
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.